Literature DB >> 10919051

Evaluation of PCNA, p53, K-ras and LOH in endocrine pancreas tumors.

T Sato1, K Konishi, H Kimura, K Maeda, K Yabushita, M Tsuji, A Miwa.   

Abstract

BACKGROUND/AIMS: The object of this study was to evaluate the characters of the endocrine pancreas tumors including proliferative activity, p53 mutation, K-ras mutation and microsatellite instability.
METHODOLOGY: The 13 endocrine tumors of the pancreas were enrolled in this study. There were 8 hypervascular tumors and 4 normo- or hypovascular tumors. All cases were immunohistochemically characterized in paraffin sections for the presence of proliferating cell nuclear antigen and p53 protein. Mutation in K-ras at codon 12 was detected by the Mutant-allele-specific amplification system. Microsatellite instability was examined by using frozen tissues in the 2 cases.
RESULTS: Proliferating cell nuclear antigen labeling index range was 0.00-0.62 (0.26 +/- 0.23). p53 was positive in 4/13 tumors. K-ras codon 12 mutation was not detected in any tumors. PCNA LI was significantly lower in hypervascular tumors (0.16 +/- 0.20) than normo- or hypovascular tumors (0.44 +/- 0.17) (P < 0.05). PCNA LI was significantly lower in the p53-positive tumors (0.48 +/- 0.17) than the p53-negative tumors (0.17 +/- 0.18) (P < 0.05). K-ras codon 12 mutation was not detected in any tumors. Loss of heterozygosity in 3p was detected in 1 tumor.
CONCLUSIONS: Hypervascular endocrine pancreas tumors have low proliferative activity. p53 mutation influences proliferation as the late event of tumor progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10919051

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  3 in total

1.  A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions.

Authors:  B Karthik Grandhi; Arvind Thakkar; Jeffrey Wang; Sunil Prabhu
Journal:  Cancer Prev Res (Phila)       Date:  2013-09-26

2.  Expression of cell cycle regulator p57kip2, cyclinE protein and proliferating cell nuclear antigen in human pancreatic cancer: an immunohistochemical study.

Authors:  Hui Yue; Hui-Yong Jiang
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

3.  Expression of p57kip2, Rb protein and PCNA and their relationships with clinicopathology in human pancreatic cancer.

Authors:  Hui Yue; Yan-Li Na; Xin-Li Feng; Shu-Ren Ma; Fu-Lin Song; Bo Yang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.